Doug Carlson is the chief financial officer and chief business officer of Avalyn Pharma. Mr. Carlson brings over 23 years of experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development and commercial roles with both large and emerging growth biopharma companies.

Prior to Avalyn, Mr. Carlson served as the CFO and COO of Avenge Bio, a clinical-stage, biotech company focused on developing cell-based immunotherapies. Prior to Avenge, he was the CFO and COO of Ikena Oncology (NASDAQ: IKNA) where he led the company’s $120 million Series B and $144 million initial public offering (IPO). Mr. Carlson previously worked at Collegium Pharmaceutical (NASDAQ: COLL) and held numerous roles during his tenure as Vice President of Corporate Development, Business Development and Commercial Operations. At Collegium, he was a member of the management team that led its transformation from a private, clinical-stage company with approximately 15 employees to a publicly traded, commercial business with over 300 employees.

Earlier in his career, Mr. Carlson held senior corporate and business development roles with BTG plc (LSE: BTG, acquired by Boston Scientific), Lundbeck, Inc. (US HQ of H. Lundeck A/S) and Ovation Pharmaceuticals (acquired by H. Lundbeck A/S). Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. He started his career in the healthcare investing banking group of Cowen & Co. Mr. Carlson received a Bachelor of Arts degree from Trinity College in Hartford, CT.